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Visual Abstract
While BDNF is receiving considerable attention for its role in synaptic plasticity and in nervous system dysfunc-
tion, identifying brain circuits involving BDNF-expressing neurons has been challenging. BDNF levels are very low
in most brain areas, except for the large mossy fiber terminals in the hippocampus where BDNF accumulates at
readily detectable levels. This report describes the generation of a mouse line allowing the detection of single
brain cells synthesizing BDNF. A bicistronic construct encoding BDNF tagged with a P2A sequence preceding
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GFP allows the translation of BDNF and GFP as separate proteins. Following its validation with transfected cells,
this construct was used to replace the endogenous Bdnf gene. Viable and fertile homozygote animals were
generated, with the GFP signal marking neuronal cell bodies translating the Bdnf mRNA. Importantly, the
distribution of immunoreactive BDNF remained unchanged, as exemplified by its accumulation in mossy fiber
terminals in the transgenic animals. GFP-labeled neurons could be readily visualized in distinct layers in the
cerebral cortex where BDNF has been difficult to detect with currently available reagents. In the hippocampal
formation, quantification of the GFP signal revealed that 10% of the neurons do not translate the Bdnf mRNA
at detectable levels, with the highest proportion of strongly labeled neurons found in CA3.
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Introduction
Brain-derived neurotrophic factor (BDNF) is a secreted
growth factor required for the development and function of
the nervous system (Mitre et al., 2017). In humans, de-
creased levels of BDNF have been associated with a wide
range of conditions, including neurodegeneration (Mariga
et al., 2017). In addition, there is considerable evidence for a
role of BDNF in depression (Castrén and Kojima, 2017) and
memory (Egan et al., 2003; Heldt et al., 2007). There are
large differences in the levels of Bdnf transcription between
different brain regions and from one neuron to the next as
long documented by in situ hybridization studies in the adult
brain of mice, rats, and pigs (Hofer et al., 1990; Wetmore
et al., 1990). Given that Bdnf transcription is regulated by
neuronal activity in excitatory neurons (Tao et al., 1998),
different degrees of activity most likely contribute to these
differences. However, comparisons between the staining
intensity of BDNF with surrogate markers of activity such as
Arc (Dieni et al., 2012; Nikolaienko et al., 2018) suggest that
other determinants are also likely to play a role. To better
understand the mechanisms regulating the translation of
BDNF and to facilitate the development of new drugs tar-
geting BDNF-expressing neurons, it is desirable to use ap-
proaches allowing the characterization of single cells as a
function of the intensity of a reporter signal such as GFP.
Feasibility is suggested by previous work using vectors en-
coding the regulatory sequences of Bdnf to drive the ex-
pression of reporters including GFP (Guillemot et al., 2007;
Koppel et al., 2009; Fukuchi et al., 2017). In addition, detect-
able levels of fluorescence have been illustrated using se-
quences encoding fluorescent proteins inserted within
activity-dependent exons of Bdnf (Singer et al., 2018). These
previous results indicate that the strength of the Bdnf pro-
moters drives levels of GFP expression sufficient to allow
single-cell visualization and sorting. Here we report on the
substitution of the Bdnf gene by a construct containing a
bicistronic mRNA encoding Bdnf and Gfp separated by a
short sequence designated P2A previously shown to pre-
vent the elongation of the peptide chain (Szymczak et al.,
2004). Fertile homozygote animals were generated using
this construct to replace the Bdnf coding sequence. Brain
sections of the corresponding transgenic animals revealed
marked differences in the levels of GFP expression between
neurons. The results are discussed in the context of a recent
report describing the generation of a mouse line with the
Bdnf gene replaced by a construct encoding a BDNF–GFP
fusion protein (Leschik et al., 2019) and of RNA sequencing
using single cells isolated from the mouse hippocampus
(Habib et al., 2016).
Materials and Methods
Constructs, HEK293 cell culture, transfection, and
BDNF measurements
Plasmid pCMV6-BDNF was generated by inserting a
PCR fragment encoding the full-length mouse BDNF pro-
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Significance Statement
BDNF is a highly conserved growth factor known to be essential for the function of the nervous system. Its
very low abundance in the brain has retarded the development of drugs targeting BDNF-expressing neurons
in disease-relevant brain areas. The present report describes a novel approach allowing the localization of
single cells in the adult mouse brain actively translating Bdnf mRNAs using GFP as a surrogate marker. The
availability of these transgenic animals will also help in understanding the action of drugs such as ketamine
that are thought to act by increasing Bdnf translation.
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tein into the BamHI site of pCMV6 (catalog #39857, Ad-
dgene; Hofer et al., 1990). pCMV–BDNF–myc was
constructed by adding one copy of a myc tag at the C
terminus of WT BDNF following deletion of the last 3 aa
(Matsumoto et al., 2008). To generate BDNF expression
constructs containing tandem repeats of myc tags, one
SbfI site was first introduced into pCMV–BDNF–myc by
PCR followed by inserting multi-copies of myc tags into
the SbfI site of the resultant plasmid pCMV-BDNF-myc-
SbfI.
The following BDNF–GFP and P2A-SV40-NLS-GFP
DNA fragments were synthesized at GeneArt (Germany):
Bdnf-Gfp (PacI, BamHI, and AscI restriction sites are
underlined): ttaattaagccaccatgaccatcctgtttctgacca
tggtcatcagctacttcggctgcatgaaggccgctcccatgaaggaagtga
acgtgcacggccagggcaacctggcttatcctggcgtgcggacacacgg
caccctggaatctgtgaacggccctagagctggcagcagaggcctgacc
acaacaagcctggccgacaccttcgagcacgtgatcgaggaactgctgg
acgaggaccagaaagtgcggcccaacgaggaaaaccacaaggacgccga
cctgtacaccagcagagtgatgctgagcagccaggtgcccctggaaccc
cctctgctgttcctgctggaagagtacaagaactacctggacgccgcca
acatgagcatgagagtgcggagacacagcgacccagctagaagaggcga
gctgagcgtgtgcgacagcatcagcgagtgggtcacagccgccgacaag
aaaaccgccgtggacatgtctggcggcaccgtgaccgtgctggaaaagg
tgccagtgtccaagggccagctgaagcagtacttctacgagacaaagtg
caaccccatgggctacaccaaagagggctgcagaggcatcgacaagaga
cactggaacagccagtgcagaaccacccagagctacgtgcgggccctga
caatggacagcaagaaaagaatcggctggcggttcatcagaatcgacac
cagctgcgtgtgcaccctgaccatcaagagaggcagaggatccggcatg
gtgtctaagggggaggaactgttcaccggcgtggtgcccatcctggtgg
aactggatggcgacgtgaacggacacaagttcagcgtgtccggcgaggg
cgaaggcgacgccacatacggaaagctgaccctgaagttcatctgcacc
accggcaagctgcccgtgccttggcctaccctcgtgaccacactgacct
acggcgtgcagtgcttcagcagataccccgaccatatgaagcagcacga
cttcttcaagagcgccatgcccgagggctacgtgcaggaaagaaccatc
ttctttaaggacgacggcaactacaagaccagggccgaagtgaagttcg
agggcgacaccctcgtgaacagaatcgagctgaagggcatcgacttcaa
agaggacggcaacatcctgggccacaagctggagtacaactacaacagc
cacaacgtgtacatcatggccgacaagcagaaaaacggcatcaaagtga
acttcaagatccggcacaacatcgaggacggctccgtgcagctggccga
ccactaccagcagaacacccctatcggcgacggccctgtgctgctgcct
gacaaccactacctgagcacccagtccgccctgagcaaggaccccaacg
agaagagggaccacatggtgctgctggaattcgtgaccgccgctggcat
caccctgggcatggacgagctgtacaaatgaggcgcgcc;
P2a-Sv40nls-Gfp (BamHI and AscI restriction sites are
underlined): ggatccggcgccaccaatttcagcctgctgaaacagg
ccggcgacgtggaagagaaccctggccctccaaagaagaagcggaag
gtcatggtgtccaagggcgaggaactgttcaccggcgtggtgcccat
cctggtggaactggatggcgacgtgaacggccacaagttcagcgtgt
ccggcgagggcgaaggcgacgccacctatggcaagctgacactgaag
ttcatctgcaccaccggcaagctgcccgtgccttggcctaccctcgt
gacaaccctgacctacggcgtgcagtgcttcagcagataccccgacc
acatgaagcagcacgacttcttcaagagcgccatgcccgagggctac
gtgcaggaacggaccatcttctttaaggacgacggcaactacaagac
cagggccgaagtgaagttcgagggcgataccctcgtgaaccggatcg
agctgaagggcatcgacttcaaagaggacggcaacatcctgggccac
aagctggagtacaactacaacagccacaacgtgtacatcatggccga
caagcagaaaaacggcatcaaagtgaacttcaagatcaggcacaaca
tcgaggacggctccgtgcagctggccgaccactaccagcagaacacc
cccatcggagatggccccgtgctgctgcccgacaaccactacctgag
cacacagagcgccctgtccaaggaccccaacgagaagagggaccaca
tggtgctgctggaatttgtgaccgccgctggcatcacactgggcatg
gacgagctgtacaagtgaggcgcgcc.
The PacI/AscI restricted BDNF–GFP fragment was li-
gated into the identically restricted pAAV plasmid (Kästle
et al., 2018). The BDNF-P2A-GFP expression plasmid
was generated by exchanging the BamHI-AscI fragment
from the before described plasmid by the BamHI-AscI
gene synthesis fragment containing the teschovirus-1
P2A, the SV40 nuclear localization signal and the GFP
coding sequences.
The biosynthesis and secretion of tagged BDNF pro-
teins were analyzed using HEK293 cells transfected with
plasmids encoding wild-type (WT) BDNF, BDNF–GFP,
and BDNF-P2A-GFP. The enhanced version of GFP was
used throughout. Cultures were maintained in Gibco
DMEM supplemented with 10% FBS, 1% GlutaMAX and
1% nonessential amino acids (all Thermo Fisher Scien-
tific). Transfections were performed in a six-well format
using 2 g of the indicated DNAs combined with 4 l of
Invitrogen Lipofectamine 2000 transfection reagent
(Thermo Fisher Scientific) diluted within Gibco Opti-MEM
medium (Thermo Fisher Scientific). Five hours after trans-
fection, HEK293 cells were cultured in N2B27 medium
consisting of equal volumes of Gibco Neurobasal medium
and DMEM-F12 (Thermo Fisher Scientific), 1% B27 sup-
plement (Thermo Fisher Scientific), 1% GlutaMAX, and
1% penicillin-streptomycin (Gibco Penstrep, Thermo
Fisher Scientific). BSA (Sigma-Aldrich) was used at a
reduced concentration of 75 g/ml to facilitate the anal-
ysis of the conditioned media by SDS-PAGE. BDNF levels
were quantified in conditioned media, and brain lysates by
ELISA (Naegelin et al., 2018).
Primary neuronal culture and transfection
Cortices of mice at embryonic day 14.5 (E14.5) for
transfection and TrkB phosphorylation assays and E17.5
for immunostaining studies were collected in Hanks’ buff-
ered salt solution (Sigma-Aldrich) and trypsinized in 1
mg/ml trypsin (Worthington) for 20 min at 37°C. The re-
action was then stopped using 1 mg/ml trypsin inhibitor
(Sigma-Aldrich) before the addition of 1 mg/ml DNase I
(Thermo Fisher Scientific) and gentle dissociation with a 5
ml serological pipette. Cells were then pelleted by centrif-
ugation at 1400 rpm for 5 min and resuspended in DMEM
supplemented with 2% FBS, 1% GlutaMAX, and 1%
Penstrep. Three hours after plating into wells coated with
poly-D-lysine (Sigma-Aldrich), cells were maintained in
Neurobasal medium supplemented with 1% GlutaMAX
supplement, 1% Penstrep, and 2% SM1 supplement
(Stem Cell Technologies). Neurons were cultured for up to
12 d with 50% media changes performed three times
weekly. Subsequent transfections were performed on
E14.5 neurons at 5DIV using 0.5 g of indicated DNAs
and 1 l of Lipofectamine 2000 (see above). Depolariza-
tion of E17.5 neurons at DIV11 was achieved by supple-
menting media with 1 mM 4-aminopyridine (4-AP; Merck)
for 24 h.
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Imaging and staining of neuronal cultures
Twenty-four hours after transfection or treatment with
4-AP, neurons were briefly washed with PBS and fixed
with 4% paraformaldehyde (PFA; Thermo Fisher Scien-
tific) for 15 min. After a 5 min permeabilization with PBS
containing 0.1% Triton X-100 (PBS-T; Sigma-Aldrich),
cells were incubated for 1 h in blocking solution [3%
donkey serum (Sigma-Aldrich) and 1% BSA in PBS-T] at
room temperature (RT). Coverslips were then incubated
overnight in primary antibodies diluted in blocking solu-
tion at the following concentrations: anti-BDNF mAb #9 (7
g/ml; Kolbeck et al., 1999), chicken anti-GFP (1:1000;
catalog #ab13970, Abcam), chicken anti-MAP2 (1:5000;
catalog #ab92434, Abcam), and rabbit anti-Tau (1:5000;
catalog #ab64193, Abcam). Following three 5 min washes
in PBS-T, cells were incubated in Invitrogen Alexa Fluor
555-conjugated anti-mouse IgG (catalog #A-31570,
Thermo Fisher Scientific), Invitrogen Alexa Fluor 488-
conjugated anti-chicken IgY (catalog #A-11039, Thermo
Fisher Scientific), Invitrogen Alexa Fluor 647-conjugated
anti-chicken IgY (Invitrogen, catalog #A-21449, Thermo
Fisher Scientific), and Invitrogen Alexa Fluor 647-con-
jugated anti-rabbit IgG (catalog #A-21245, Thermo Fisher
Scientific) secondary antibodies in blocking solution (all at
1:500 dilutions) for 1 h. After a 5 min wash with PBS-T,
DAPI (Sigma-Aldrich) diluted in PBS (1:4000) was added
to cells for 15 min. Coverslips were then mounted onto
glass slides using Dako fluorescence mounting medium
(Agilent). Images were captured using a 63 objective of
a confocal microscope and are shown as maximum in-
tensity projections of z-stack images (LSM 780, Carl
Zeiss).
TrkB phosphorylation assay of cultured neurons
The conditioned media of transfected HEK293 cells
transfected with BDNF cDNAs were standardized to a
BDNF concentration of 25 ng/ml after quantification using
a BDNF ELISA (Naegelin et al., 2018). Before treatment,
E14.5 neurons at 5DIV were incubated with fresh media
for 15 min to aid clearance of endogenous phosphoryla-
tion. Cells were then incubated with conditioned media
containing WT BDNF or BDNF-P2A for 10 min. Cells were
then washed using PBS supplemented with 2 mM sodium
orthovanadate (Sigma-Aldrich) to inhibit phosphatase ac-
tivity and analyzed by SDS-PAGE for TrkB phosphoryla-
tion.
Western blot and densitometric analysis
Homogenized brain tissues, HEK293 cells, and cultured
neurons were incubated for 20 min on ice in RIPA buffer
(50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 0.1% SDS,
0.2% sodium deoxycholate, and 1% Triton X-100) sup-
plemented with phosphatase and protease inhibitor cock-
tail mixes, 10 M phenanthroline monohydrate, 10 mM
aminohexanoic acid, 10 g/ml aprotonin, and 2 mM so-
dium orthovanadate (all Sigma-Aldrich). Lysates and con-
ditioned media were centrifuged at 15,000 rpm to remove
insoluble components before analysis by SDS-PAGE.
Proteins were separated on 4–12% NuPAGE Bis-Tris gels
(Invitrogen) and transferred to GE Healthcare Protran NC
nitrocellulose membranes (Thermo Fisher Scientific) using
a Trans-Blot semi-dry transfer unit (Bio-Rad). Membranes
were subsequently blocked for 1 h in blocking solution
[5% blotting-grade blocker (Bio-Rad) and 1% BSA in TBS
containing 0.1% Tween (TBS-T; Sigma-Aldrich)] and then
probed overnight at 4°C with antibodies to -actin (cata-
log #ab8229, Abcam), BDNF (monoclonal 3C11, catalog
#327-100, Icosagen), BDNF propeptide (monoclonal
5H8, catalog #sc-65514, Santa Cruz Biotechnology), GFP
(catalog #ab13970, Abcam), or phosphoTrkA (Tyr674/
675)/TrkB (Tyr706/707, catalog #4621, Cell Signaling
Technology) in blocking solution (1:2000). Following three
10 min washes in TBS-T, membranes were incubated at
RT with HRP-conjugated anti-goat (Santa Cruz, catalog
#sc-2354), anti-mouse, anti-rabbit (both Promega, cata-
log #W4021 and W4011 respectively) or anti-chicken (Ab-
cam, catalog #ab6877) secondary antibodies within
blocking solution (1:2000). After a further three 20 min
washes in TBS-T, membranes were developed using
WesternBright ECL HRP Substrate (Advansta). Densito-
metric analysis of all blots was performed using quantifi-
cation functions on Bio-Rad ImageLab software. For blots
requiring BDNF quantification, recombinant BDNF stan-
dards (Regeneron/Amgen) between 300 and 18.75 pg
were run alongside to create calibration curves, as appro-
priate.
Animal husbandry and generation of Bdnf-P2a-Gfp
animals
All animals in this study were approved by the Cardiff
University Ethical Review Board, and all experiments were
performed within the guidelines of the Home Office Ani-
mals (Scientific Procedures) Act, 1986. Bdnf knock-out
(Bdnf/) animals were generated by crossing mice with
two floxed Bdnf alleles (Rauskolb et al., 2010) with mice
expressing a CMV-Cre transgene (Schwenk et al., 1995).
Bdnf-P2a-Gfp animals were generated by Taconic Biosci-
ences. Briefly, the targeting strategy is based on NCBI
transcript NM_001048139.1 and Ensemble gene ID ENS-
MUSG00000048482, in which exon 2 contains the com-
plete BDNF coding sequence. The GSG sequence is then
followed by the teschovirus P2A sequence (Liu et al.,
2017), the SV40 nuclear localization sequence (NLS; Ray
et al., 2015) and a GFP sequence inserted between the
last amino acid and the translation termination codon in
exon 2 of the BDNF coding sequence. The presence of
the P2A sequence should result in the cotranslational
generation of BDNF and NLS-GFP proteins. For the se-
lection of positively targeted C57BL/6N Tac embryonic
stem (ES) cells, a puromycin selection marker was flanked
by FRT (flippase recognition target) sites and inserted into
intron 1. The puromycin selection cassette was deleted in
ES cells by transient expression of Flp recombinase. The
remaining FRT recombination site is located in a non-
conserved region of the genome and thus unlikely to
interfere with BDNF expression. After blastocyst injection
of targeted ES cells, chimeric animals were bred to
C57BL/6N Tac mice to obtain heterozygous offspring. For
colony expansion purposes, heterozygous breeding pairs
were set up, with litters displaying normal Mendelian birth
ratios; among 65 animals from eight litters, the distribution
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was as follows: wild type, n  19; heterozygotes, n  30;
and homozygotes, n  16. Animals of both sexes were
used throughout the study, and the only sex-related dif-
ferences were illustrated (see Fig. 3C). After confirming
the fertility of homozygotes, the colony was then main-
tained using a mixture of breeding pairs. From 3 to 4
weeks of age, animals were housed in mixed genotypes
and were maintained on a 12 h dark/light cycle, with
access to food and water ad libitum.
Tissue fixation and immunostaining
Three-month-old mice killed by pentobarbital injections
were transcardially perfused with ice-cold PBS and 4%
PFA, and their brains were removed and postfixed at RT
for 4 h before cryoprotecting in 30% w/v sucrose solution
at 4°C overnight. The following day, brains were embed-
ded in OCT (optimal cutting temperature) compound and
sectioned at 40 m using a cryostat. Sections were
blocked in blocking solution (3% donkey serum and 4%
BSA in PBS-T) for 1 h before incubating overnight with
mouse anti-BDNF (mAb #9) and chicken anti-GFP (1:
1000). Sections were then washed three times for 10 min
with PBS-T before incubating with Alexa Fluor 555 anti-
mouse IgG and Alexa Fluor 488 anti-chicken IgY second-
ary antibodies (1:500; Thermo Fisher Scientific) for 1 h at
RT. After a final wash in PBS-T for 10 min, sections were
incubated with DAPI diluted in PBS (1:4000) for 20 min
and mounted onto precoated polylysine slides (VWR) with
Dako fluorescence mounting media. Images of gross
brain regions were acquired on a confocal microscope
using a 20 objective. For counts of GFP-positive nuclei,
images were captured using a 63 oil-immersion and
then analyzed using FIJI (Schindelin et al., 2012) and
CellProfiler (McQuin et al., 2018). For each section, masks
were created on FIJI to focus automated analyses onto
granule cells of the dentate gyrus (DG) and pyramidal cells
of CA1, CA2, and CA3. On CellProfiler, DAPI and GFP-
positive nuclei were then identified using individual Iden-
tifyPrimaryObjects modules. GFP immunostaining was
measured using MeasureObjectIntensity, and identified
nuclei were categorized using custom-defined bins ac-
cording to their staining intensity (under categories “Be-
low Threshold,” “Light,” “Moderate,” “Heavy,” or “Very
Heavy”).
Statistical analysis
Data were analyzed using Microsoft Excel 2013 and
RStudio software. For analysis of Bdnf-P2a-Gfp body-
weights, a Kruskal–Wallis test was used with a Conover-
Iman post hoc test for multiple comparisons. TrkB
activation by BDNF fusion proteins was compared against
that of BDNF-myc and analyzed using a one-sample t
test. An adjusted p value (0.0125) was considered sig-
nificant after a Bonferroni correction for multiple compar-
isons. Differences in BDNF and GFP signal intensities in
depolarized Bdnf-P2a-Gfp neurons were analyzed using a
Student’s t test. All results were expressed as the mean
SE, and p  0.05 was considered to be significant unless
otherwise stated.
Results
In vitro experiments with transfected cells
As the biosynthesis and secretion of biologically active
BDNF is a prerequisite for the generation of viable ani-
mals, the suitability of candidate Bdnf constructs was first
tested using transfected HEK293 cells. Constructs en-
coding unmodified BDNF, BDNF directly fused with GFP
or separated from BDNF by a P2A sequence (Fig. 1A),
was introduced into expression vectors and used to
transfect HEK293 cells with Lipofectamine. The GFP se-
quence adds 238 aa to the C terminal of the BDNF, while
P2A adds 22 aa. Both cell lysates and conditioned media
were collected and probed with the BDNF monoclonal
antibody 3C11. This antibody unambiguously identifies
BDNF in Western blot, as demonstrated by the absence of
signal in lysates prepared from the cerebral cortex of
Bdnf/ animals (Fig. 1B). In transfected cells, unlike in
the case with neurons expressing endogenous Bdnf (Ma-
tsumoto et al., 2008), a significant proportion of the im-
munoreactive material in cell lysates migrates as pro-
BDNF identified using the pro-BDNF antibody 5H8 (data
not shown) that can also be detected in the conditioned
medium (Fig. 1C). In cell lysates of cells transfected with
BDNF–GFP constructs, significant levels of pro-BDNF–
GFP can be detected with the anti-BDNF antibody, while
BDNF–GFP is barely detectable in the conditioned me-
dium (Fig. 1D). By contrast, the bulk of pro-BDNF-P2A is
clearly separated from BDNF-P2A, and both are readily
detectable in the conditioned medium (Fig. 1C). The up-
ward shift of BDNF-P2A compared with recombinant
BDNF indicates that the P2A sequence remains attached
to BDNF (Fig. 1C). Cell lysates probed with GFP antibod-
ies confirm the biosynthesis of BDNF and GFP as sepa-
rate products when encoded by the BDNF–P2A–GFP
construct, unlike the case for the BDNF–GFP fusion con-
struct, with the bulk of the immunoreactive material de-
tected as unprocessed pro-BDNF–GFP (Fig. 1D).
As transfected HEK293 cells do not have a dedicated
secretory pathway comparable to neurons, the same
three constructs were also used to transfect cultured
cortical neurons (Fig. 2). The WT BDNF expression con-
structs revealed intense staining of neuronal cell bodies
as well as dotted staining of MAP2-positive processes
(Fig. 2A). With BDNF–GFP constructs, a GFP signal was
observed throughout the transfected neurons with the
GFP signal partially overlapping with the BDNF immuno-
reactive signal (Fig. 2B, arrowheads), possibly indicating
that a fraction of GFP separates from BDNF (see Discus-
sion). Neurons transfected with the BDNF–P2A constructs
revealed a GFP signal largely overlapping with the nu-
cleus, confirming the biosynthesis of BDNF and GFP as
separate products in transfected neurons (Fig. 2C).
Characterization of transgenic animals carrying the
Bdnf–P2a–Gfp replacement construct
Having established the suitability of the BDNF–P2A–
GFP construct with regard to the biosynthesis and secre-
tion of BDNF as well as the biosynthesis of BDNF and
GFP as distinct products, this construct was then used to
replace the protein-coding region of the endogenous Bdnf
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Figure 1. Constructs, validation of the monoclonal antibody 3C11, and transfection of HEK293 cells with BDNF expression plasmids.
A, Schematic representation of BDNF plasmid translation products. B, Validation of monoclonal antibody 3C11 for BDNFWestern blot
using brain lysates from Bdnf WT, heterozygous (Het), and knock-out (KO) littermates at postnatal day 7. C, D, Western blot analysis
of cell lysates and conditioned media using anti-BDNF (mAb 3C11; C) and anti-GFP (D). Cells were transfected with the indicated
plasmids. Note that three times more conditioned media was loaded into lanes for BDNF–GFP to aid detection of low levels.
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gene. Following mating of heterozygote animals, homozy-
gote animals carrying the Bdnf–P2a–Gfp construct were
born at the expected Mendelian ratio (see Materials and
Methods). In addition, the transgene did not measurably
interfere with the fertility of the animals. Coronal brain
sections of homozygous animals were then examined by
confocal microscopy following perfusion, fixation, and
staining with antibodies to GFP, BDNF, as well as nuclear
staining with DAPI (Fig. 3A). The distribution of the BDNF
signal is in line with previous BDNF staining experiments
using BDNF antibodies (Conner et al., 1997; Yan et al.,
1997; Dieni et al., 2012), while the distribution of the GFP
signal corresponds to the results of previous in situ hy-
bridization studies (see also Allen brain atlas, http://
mouse.brain-map.org/gene/show/11850). Selective GFP
labeling can be readily observed in distinct cortical layers,
including layers 2, 5, and 6 as well as in distinct nuclei
including the amygdala as well as all subdivisions of the
Figure 2. BDNF and GFP localization in transfected primary neurons. A–C, E14.5 cortical cultures at 6DIV transfected with cDNAs
encoding WT BDNF (A), BDNF–GFP (B), and BDNF-P2A-GFP (C), and stained using antibodies against BDNF and MAP2. In all
transfections, the majority of BDNF immunoreactivity was observed in cell bodies in areas likely corresponding to the Golgi apparatus.
In BDNF–GFP transfected cells (B), the separation of GFP fluorescence (green) from BDNF immunofluorescence (magenta) was
observed in both the nucleus and proximal neurites (indicated by white arrowheads).
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Figure 3. Characterization of Bdnf-P2a-Gfp mice. A, Co-staining of BDNF and GFP homozygous Bdnf-P2a-Gfp hippocampus. Note
the clear separation of GFP and BDNF in the mossy fiber projections of hippocampal CA3. B, GFP staining of homozygote brains
reveals a comparable staining pattern to previous in situ hybridization experiments, with staining in distinct cortical layers,
hippocampal formation, and amygdala. C, Body weights of young adult (3- to 4-month old) and adult (6- to 7-month old)
Bdnf-P2a-Gfp mice. While there were no significant differences observed between littermates during young adulthood, significant
weight gain could be observed in both heterozygous and homozygous males by 6–7 months of age (p  0.0100 and p  0.0017,
respectively). The bars represent the mean weights  SE, n  7 across genotypes and age categories. D, Western blot analysis of
adult Bdnf-P2a-Gfp brain lysates. Note the shift in the molecular weight of BDNF after the addition of the P2A sequence, and the
separation of BDNF-P2A from GFP in Bdnf-P2a-Gfp heterozygous (Het) and homozygous (Hom) animals (two animals shown per
genotype).
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hippocampal formation (Fig. 3A,B). Quantification of the
GFP signal using CellProfiler (Materials and Methods) re-
vealed that the vast majority of hippocampal neurons trans-
late the construct at readily detectable, albeit different,
levels, with the largest number of heavily labeled cells found
in CA3 and the highest proportion of weakly labeled cells
found in CA2 and CA1, and in the DG (Table 1). We also
monitored the postnatal weight gain of the Bdnf-P2a-Gfp
animals and observed that starting at 6 months, homozy-
gote animals gained more weight than their wild-type litter-
mates, a trend that was even visible in male heterozygotes
(Fig. 3C). As the literature indicates that BDNF levels and
TrkB signaling are critical in the regulation of food intake
(Lyons et al., 1999; Kernie et al., 2000), both in mice and
humans (Yeo et al., 2004), we quantified BDNF levels by
ELISA in the cerebral cortex of Bdnf-P2a-Gfp animals and
found them unchanged compared with age-matched con-
trols: (mean  SEM) 35.5  2.11 ng/g WT cortex; and 45.4
 6.38 ng/g for homozygote Bdnf-P2a-Gfp animals. The
corresponding values for the hippocampus were 97.4 
6.00 ng/g and 109.3 ng/g  17.11 for WT and homozygous
animals, respectively. To confirm that GFP is cleaved after
the BDNF–P2A sequence in vivo, we analyzed the lysates of
cortices from wild-type, heterozygote, and Bdnf-P2a-Gfp
homozygote animals by Western blot (Fig. 3D). These ex-
periments revealed a quantitative upward shift of BDNF–
P2A compared with the endogenous protein.
TrkB activation by tagged BDNF
Given the lack of evidence for abnormal processing,
levels and distribution of BDNF in cells and mice express-
ing the Bdnf–P2a–Gfp construct, we then asked whether
the length of the P2A tag added to BDNF may compro-
mise its ability to fully activate the BDNF receptor TrkB on
neurons, thus conceivably explaining the abnormal weight
gain of adult animals. This hypothesis was tested using
BDNF constructs carrying repeats of a 10 aa myc tag
used to transfect HEK293 cells. The choice of the myc tag
for these experiments was inspired by previous studies
indicating that the substitution of Bdnf by Bdnf-Myc al-
lows the generation of animals with no overt phenotypes
(Matsumoto et al., 2008; Dieni et al., 2012). The biosyn-
thesis and secretion of BDNF was assessed in cell lysates
and conditioned media using the BDNF antibody 3C11
and neither the biosynthesis nor the secretion of BDNF
carrying up to 4 myc tags seemed to be compromised
(Fig. 4A). The conditioned media were also used to test the
ability of BDNF-myc to trigger TrkB phosphorylation (Fig.
4B). Primary cultures of mouse cortical neurons were ex-
posed to HEK293 cell-conditioned media with their concen-
trations adjusted to correspond to 25 ng/ml BDNF as
determined by ELISA. The conditioned media of HEK293
cells transfected with a BDNF–P2A–GFP construct were
used in parallel (Fig. 4B). These experiments revealed that
the ability of BDNF–3 myc and especially of BDNF–4 myc
constructs to activate TrkB was reduced (Fig. 4B).
Localization and quantification of BDNF and GFP in
cultured neurons after depolarization
Having established the localization of the BDNF signal
and the segregation from the GFP signal in transfected
neurons (Fig. 2C), it was of interest to compare these
results with those obtained with neurons obtained from
the Bdnf-P2a-Gfp mouse. As illustrated in Figure 5, the
results are indistinguishable from those obtained with
wild-type neurons stained with BDNF antibodies, indicat-
ing that the P2A tag does not significantly interfere with
the distribution of BDNF. To test whether the intensity of
the GFP signal is proportional to the BDNF immunoreac-
tive signal, both were quantified before and after depolar-
ization with 1 mM 4-AP. Both signals were found to
increase by more than twofold after 24 h (Fig. 5).
Discussion
The main conclusion of this study is that GFP can be
used as a surrogate marker to identify cells translating the
Bdnf mRNA in the adult mouse brain. The results also
indicate that the GFP signal intensity is proportional to the
degree of BDNF translation as revealed by experiments
with cultured neurons. While BDNF and GFP are obvi-
ously very different proteins with different half-lives, GFP
is mostly targeted to the nucleus, whereas BDNF accu-
mulates in vesicles. This differential subcellular localiza-
tion may explain why the relative signal intensities after
acute depolarization do not perfectly match quantitatively
(Fig. 5). In the brain, the distribution of the GFP is in
remarkable agreement with the known distribution of the
Bdnf signal observed in previous in situ hybridation stud-
ies, including the Allen Brain Atlas (http://mouse.brain-
map.org/gene/show/11850). Importantly, the distribution
of the endogenous BDNF protein remains unchanged
when comparing the staining of BDNF in the hippocampal
formation (Fig. 3A) with previous results using antibodies
to myc- or hemagglutinin-tagged versions of the Bdnf
gene (Matsumoto et al., 2008; Yang et al., 2009). This
distribution is also in agreement with results obtained with
rat brain sections with the then available, validated BDNF
polyclonal antibodies (Conner et al., 1997; Yan et al.,
1997). The fact that neither the viability of homozygote
animals nor their fertility is compromised further suggests
Table 1: Quantification of GFP signal intensity in the hip-
pocampal formation
Region
Proportions of GFP-positive cells
Background Light Moderate Heavy Very heavy
DG 5.37% 55.26% 32.08% 6.66% 0.64%
SEM 1.79% 6.33% 5.05% 2.95% 0.24%
CA1 4.11% 65.43% 24.25% 5.39% 0.81%
SEM 1.33% 7.38% 5.43% 3.47% 0.69%
CA2 5.52% 57.25% 26.69% 9.93% 0.61%
SEM 1.55% 7.65% 4.96% 3.90% 0.26%
CA3 6.96% 31.50% 37.82% 17.58% 6.15%
SEM 0.92% 4.11% 2.05% 2.64% 1.45%
The results are based on sections from three different, 3-month-old female
homozygous animals. Five sections per animal were used, and quantifica-
tion was performed using CellProfiler (Materials and Methods). Quantifica-
tion of the GFP signal was performed by recording the intensity of the Alexa
Fluor 488 in sections stained with chicken anti-GFP primary antibody and
Alexa Fluor 488-conjugated anti-chicken IgY secondary antibody. Counts
were based on DAPI-stained nuclei in the DG granule cell layer and in the
pyramidal cell layer for CA1/CA2/CA3. All analyzed sections fell between
bregma coordinates 1.355 and 2.88.
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that BDNF-dependent circuits are likely to remain func-
tional. However, the Bdnf-P2a-Gfp mice do abnormally
gain weight several months after birth, especially in males,
suggesting that these animals may be best investigated
as young adults in future studies. As the BDNF levels are
unchanged in these animals (see Results; Fig. 1B), it is
conceivable that the 22 aa tag attached to the C terminal
of BDNF may chronically reduce TrkB activation in vivo,
thus potentially explaining the progressive weight gain
that is apparent in male animals at 6 months of age.
Submaximal activation of TrkB over extended periods of
time in vivo may impair the functionality of the circuitry
involved in the feeding behavior of the transgenic animals.
These results also suggest that there is only limited scope
to add extended tags to BDNF while fully preserving
biological activity. In particular, TrkB activation with the 4
myc tag construct (adding 40 aa) is reduced by 50%.
Caution should then be exerted when using comparatively
large fusion constructs such as BDNF–GFP as they would
seem unlikely to efficiently activate TrkB. The results pre-
sented in Figure 1 also indicate additional problems with
the processing of pro-BDNF–GFP and the secretion of
Figure 4. Increasing the length of BDNF-fusion proteins attenuates their ability to phosphorylate TrkB.A, Western blot analysis of cell lysates
and conditionedmedia using anti-BDNF (mAb 3C11). Cells were transfectedwith cDNAs encoding BDNF carryingmultiple additions of the 10 aa
myc tag.B, TrkB phosphorylation in primary neurons treated with conditionedmedia containing BDNF fusion proteins standardized to 25 ng/ml.
Note that thepotencyof TrkBphosphorylation is significantly reducedasgenetically encoded tags increase in length (BDNF-3myc, p0.00312;
BDNF-4 myc, p  0.00394). Bars representative of mean relative phosphorylation (compared with BDNF-myc)  SE.
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BDNF–GFP is barely detectable in the conditioned me-
dium of HEK293 cells transfected with BDNF–GFP con-
structs (Fig. 1). This conclusion contrasts with the results
detailed in a recent, closely related study on Bdnf gene
substitution with GFP directly coupled to the C terminal of
BDNF (Leschik et al., 2019). This gene replacement strat-
egy led to a decrease of 50% of the expected Mende-
lian ratio of animals homozygote for the replacement of
Bdnf by Bdnf-Gfp. In addition, the distribution of the GFP
signal in these animals does not report the distribution of
the endogenous BDNF protein, as exemplified by the lack
of enrichment of the GFP signal in mossy fiber terminals
(see above). It is conceivable that GFP may have been
cleaved from BDNF in the surviving animals as a func-
tional cleavage site at the C terminal of BDNF has been
noted following the isolation of BDNF from brain homog-
enates (Rodríguez-Tébar et al., 1991). However, it should
also be noted that this tentative explanation does not
account for the Western blot results included in the study
by Leschik et al. (2019).
The approach described here now opens the possibility
to use the GFP signal to isolate and sort cells from the
adult brain based on GFP signal intensity, thus allowing
their individual profiling by RNAseq. Such results would
help to inform the development of drugs selectively tar-
geting these neurons and may deliver new clues as to the
endogenous regulators of BDNF expression. Similar ob-
jectives could in principle also be reached by randomly
isolating single cells from brain regions of interest without
prior cell marking. As such data are indeed available for
the adult mouse hippocampus (Habib et al., 2016), we
compared them with those reported here. The main out-
come of this comparison is that the hierarchy is somewhat
different from what can be inferred from Bdnf mRNA
Figure 5. BDNF localization in wild-type versus homozygous Bdnf-P2a-Gfp neurons. Immunostaining of primary neurons with
antibodies against BDNF (mAb #9), GFP, and Tau. After 24 h of treatment with 4-AP, note the increased number of BDNF puncta in
neuronal projections and the increased GFP signal intensity in Bdnf-P2a-Gfp cultures. Quantification of immunostained Bdnf-P2a-Gfp
cultures revealed significant increases in both BDNF and GFP following 4-AP treatment. Quantification of immunostained Bdnf-P2a-
Gfp cultures revealed significant increases in both BDNF and GFP following 4-AP treatment (p  3.94  1021 and 7.85  1024
respectively; n  90 for both conditions).
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levels. In particular, the study by Habib et al. (2016),
indicates that the dentate gyrus contains the highest number of
cells containing Bdnf mRNA (see Bdnf in https://
portals.broadinstitute.org/single_cell/study/SCP1/-single-
nucleus-rna-seq-of-cell-diversity-in-the-adult-mouse-
hippocampus-snuc-seq#study-visualize), possibly due to the
selective inclusion of DAPI-positive cells in the granule cell and
pyramidal cell layer. We also note that the results summarized
in Table 1 closelymatch previous in situ hybridization studies in
the rat (Conner et al., 1997) and the mouse (see e.g., http://
mouse.brain-map.org/gene/show/11850).
In conclusion, the mouse line reported in this study
should facilitate the detailed characterization of brain neu-
rons actively translating the Bdnf mRNA by allowing the
selection of cells based on the intensity of the GFP signal.
This should prove useful toward the development of new
drugs aiming at selectively increasing the levels of BDNF
in brain regions of interest, including rapidly acting de-
pressants such as ketamine thought to act by increasing
BDNF translation (Björkholm and Monteggia, 2016).
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